Paul Guyre
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$7.8MFederal grants as PI12 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
12 awards · $7.8M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Mar 1, 2021 | NIH | SBIR Phase II Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus | $985K | CELDARA MEDICAL, LLC |
| Sep 11, 2020 | NIH | SBIR Phase I Biomarker of IAPP dysfunction in prediabetes and early type 2 diabetes mellitus (T2DM) | $299K | CELDARA MEDICAL, LLC |
| Sep 3, 2019 | NIH | SBIR Phase I Antimicrobial peptides to combat MDR ESKAPE pathogens | $299K | CELDARA MEDICAL, LLC |
| Feb 6, 2019 | NIH | SBIR Phase II Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus | $295K | CELDARA MEDICAL, LLC |
| Apr 17, 2018 | NIH | SBIR Phase II Development of GIFT4: a B cell focused immunotherapy for cancer | $1000K | CELDARA MEDICAL, LLC |
| Feb 15, 2018 | NIH | SBIR Phase II Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus | $300K | CELDARA MEDICAL, LLC |
| Feb 2, 2018 | NIH | SBIR Phase II Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF | $750K | CELDARA MEDICAL, LLC |
| May 12, 2017 | NIH | SBIR Phase II Development of GIFT4: a B cell focused immunotherapy for cancer | $2.0M | CELDARA MEDICAL, LLC |
| Jan 26, 2017 | NIH | SBIR Phase II Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF | $750K | CELDARA MEDICAL, LLC |
| Jul 22, 2015 | NIH | SBIR Phase II Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF | $225K | CELDARA MEDICAL, LLC |
| May 1, 2015 | NIH | SBIR Phase I Preclinical Development of BILT, a Next-Generation Immunotoxin Therapy for CTCL | $299K | CELDARA MEDICAL, LLC |
| — | NIH | SBIR Phase I Discovery of novel helminth immunomodulatory proteins for autoimmune diseases | $598K | CELDARA MEDICAL, LLC |
Peer ranks
Federal funding#120
Awards as PI#86
Patents#273
Companies
- CELDARA MEDICAL, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.